Zepatier Patent Expiration

Can you believe ZEPATIER received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7973040 MSD SUB MERCK Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Jul, 2029

(5 years from now)

US8871759 MSD SUB MERCK Inhibitors of hepatitis C virus replication
May, 2031

(6 years from now)



Zepatier is a drug owned by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc. It is used for treating patients infected with hepatitis C virus. Zepatier uses Elbasvir; Grazoprevir as an active ingredient. Zepatier was launched by Msd Sub Merck in 2016. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 04, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 28, 2021
New Patient Population(NPP) Dec 09, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

NCE-1 date: 29 January, 2020

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of patients infected with hepatitis c virus

Dosage: TABLET

More Information on Dosage

ZEPATIER family patents

Family Patents